company background image
VP2 logo

Valeo Pharma DB:VP2 Stock Report

Last Price

€0.005

Market Cap

€2.9m

7D

0%

1Y

-92.9%

Updated

04 Nov, 2024

Data

Company Financials +

VP2 Stock Overview

A specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada.

VP2 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Valeo Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Valeo Pharma
Historical stock prices
Current Share PriceCA$0.005
52 Week HighCA$0.23
52 Week LowCA$0.0045
Beta2.32
11 Month Change0%
3 Month Change-76.19%
1 Year Change-92.86%
33 Year Change-99.08%
5 Year Changen/a
Change since IPO-99.33%

Recent News & Updates

Recent updates

Shareholder Returns

VP2DE PharmaceuticalsDE Market
7D0%-1.8%-1.8%
1Y-92.9%-12.8%13.6%

Return vs Industry: VP2 underperformed the German Pharmaceuticals industry which returned -12.8% over the past year.

Return vs Market: VP2 underperformed the German Market which returned 13.6% over the past year.

Price Volatility

Is VP2's price volatile compared to industry and market?
VP2 volatility
VP2 Average Weekly Movement157.9%
Pharmaceuticals Industry Average Movement7.9%
Market Average Movement5.0%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: VP2's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: VP2's weekly volatility has increased from 118% to 158% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200370Al Moghaddamwww.valeopharma.com

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson’s disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic.

Valeo Pharma Inc. Fundamentals Summary

How do Valeo Pharma's earnings and revenue compare to its market cap?
VP2 fundamental statistics
Market cap€2.94m
Earnings (TTM)-€21.24m
Revenue (TTM)€35.29m

0.1x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VP2 income statement (TTM)
RevenueCA$53.38m
Cost of RevenueCA$41.36m
Gross ProfitCA$12.02m
Other ExpensesCA$44.14m
Earnings-CA$32.12m

Last Reported Earnings

Jul 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin22.51%
Net Profit Margin-60.18%
Debt/Equity Ratio-110.1%

How did VP2 perform over the long term?

See historical performance and comparison